

REMARKS

Upon entry of the above amendment, claims 1-2, 4-8, 10-15, 17 and 19-35 will be pending in the captioned application. The claims have been amended to incorporate the hydrates, solvates, salts, hydrates of the salts and solvates of the salts of the compounds of formula 1. Specific basis for this amendment can be found in the paragraph spanning pages 7 and 8 of the specification. Further, various clerical errors have been corrected throughout the claims.

Neither the amendments to the claims, nor the newly introduced claims, add new matter within the meaning of 35 U.S.C. §132. Accordingly, the Examiner is respectfully requested to enter the above amendment before examination. If the Examiner has any questions regarding this submission, she is invited to telephone the undersigned attorney.

Respectfully submitted,
NATH & ASSOCIATES PLLC

By: 


Gary M. Nath
Registration No. 26,965
Sheldon M. McGee
Registration No. 50,454
Customer No. 34375

Date: February 3, 2005
NATH & ASSOCIATES PLLC
1030 15th Street NW, 6th Floor
Washington, D.C. 20005-1503
(202)-775-8383

DT05 Rec'd OCT/PTO 03 FEB 2005

Appendix BAbstract of the Disclosure

The compounds of a certain formula (1),



in which the given substituents have the meanings as given
in the description, are novel effective PDE4 inhibitors.